We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease

By LabMedica International staff writers
Posted on 25 Jun 2026

Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. More...

This gap has limited sex-specific diagnostic and prognostic tools. A new study now identifies a female-specific chimeric RNA that influences blood cell development and is associated with COVID-19 severity.

At the University of Virginia (UVA) School of Medicine, investigators identified UBA1-CDK16, a chimeric RNA found only in women. Chimeric RNAs are molecules assembled from parts of different genes rather than a single locus. UBA1-CDK16 originates from the inactive X chromosome and can be detected in women’s blood.

The team linked UBA1-CDK16 to hematopoiesis and immune regulation in women. The RNA’s female specificity reflects X-chromosome biology, with the inactive X producing this sequence despite global silencing. The authors highlight that chimeric RNAs, once regarded as cancer byproducts, can also be part of normal physiology with regulatory functions.

Findings reported that UBA1-CDK16 was absent in 50% of women who developed severe COVID-19, while it remained present in women who were asymptomatic. Lower levels of the RNA tracked with increasing infection severity. The researchers also suggest a role in governing neutrophil development, consistent with known links between neutrophil counts and COVID-19 outcomes.

The work appears in Science Advances on May 29, 2026. The study was conducted in UVA’s Department of Pathology in collaboration with the UVA Comprehensive Cancer Center. The authors add that UBA1-CDK16 may act as a natural brake on excessive autoimmune activity in women and could inform development of blood-based tests to diagnose disease or stratify risk, pending additional research.

“Chimeric RNAs are RNA molecules composed of parts from different genes. They were once believed to be cancer-specific. However, our research shows that they can also be part of normal physiology and play important roles in human health,” said Hui Li, Ph.D., of the Department of Pathology and the UVA Comprehensive Cancer Center, University of Virginia.

"This finding highlights that there is another layer of control for gene expression. These chimeric RNAs may represent a hidden repertoire for biomarkers and therapy targets as well," said Li.

Related Links
UVA School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.